10x Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
The Form 8-K reports that 10x Genomics entered into a global settlement and patent cross-license agreement with Bio-Rad Laboratories dated July 26, 2021. The settlement, announced July 27, 2021, resolves all outstanding litigation and proceedings between the companies worldwide and dismisses all infringement claims with prejudice.
Financial and Operating Impacts
- 10x Genomics and Bio-Rad granted each other non-exclusive, worldwide, royalty-bearing licenses covering products and services related to single-cell analysis.
- The licenses exclude spatial analysis and In Situ analysis products, and exclude digital PCR products in the case of 10x Genomics.
- Each company will pay royalties to the other on licensed products and services through 2030. The company expects future royalty payments to reduce gross margins by less than 1% during the royalty period.
- 10x Genomics had accrued $44.8 million of royalties and interest related to GEM product sales from November 14, 2018 through March 31, 2021. Under the settlement, it will pay Bio-Rad $29.4 million for that period.
- The company expects to reverse $15.4 million of accrued royalties and interest in its second-quarter 2021 financial statements.
- The filing does not provide revenue, net income, cash flow, debt, liquidity, or other broader financial metrics.
Material Changes, Outlook, and Risks
- The settlement removes the disclosed litigation exposure between the parties and establishes ongoing cross-licensing obligations.
- The expected $15.4 million reversal should benefit second-quarter 2021 results relative to the previously accrued liability; the filing does not specify the precise income-statement classification or cash impact.
- Management expects the recurring royalty burden to have a less-than-1% gross-margin impact, but the amount may vary with licensed-product and service sales.
- Forward-looking statements include expectations regarding future sales and royalties, gross-margin effects, and the accrued-royalty reversal.
- Risks include the agreement’s impact on the business, general economic conditions, the company’s financial condition, and the risk factors in its Forms 10-K and 10-Q. The agreement contains confidential redactions, and the filing cautions that actual results may differ from expectations.
Important Facts for Investors to Verify
- Confirm recognition of the $15.4 million accrued royalty and interest reversal in second-quarter 2021 results.
- Verify the $29.4 million settlement-related royalty payment and its cash-flow treatment.
- Track royalty expense and gross-margin effects through 2030.
- Review the redacted Settlement and Patent Cross License Agreement for material terms not disclosed in the filing.
- Assess whether the licensed-product exclusions affect 10x Genomics’ spatial analysis, In Situ analysis, or digital PCR strategy.